Recent Asundexian News
On November 19, Bayer announced to stop the OCEANIC-AF trial, a phase III study investigating asundexian compared to apixaban (a direct oral anticoagulant) in patients with atrial fibrillation at risk for stroke. This decision is based on the recommendation of the study’s Independent Data Monitoring Committee (IDMC) as part of ongoing surveillance which showed an inferior efficacy of asundexian versus the control arm. Bayer will further analyze the data to understand the outcome and publish the data.
The purpose of this webinar is to share the background and Bayer’s first assessments with the financial community, and to allow for Q&A.
Company representatives attending the webinar will be Bill Anderson (CEO of Bayer AG), Wolfgang Nickl (CFO of Bayer AG), Stefan Oelrich (President of Bayer’s Pharmaceuticals Division and Member of the Board of Management, Bayer AG) and Christian Rommel (Global Head of R&D of Bayer’s Pharmaceuticals Division).
Tuesday, November 21, 2023 // 14:00 p.m. CET (13:00 p.m. UTC):
